{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:10:24Z","timestamp":1776669024661,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004417","name":"Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43655-w","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:53:06Z","timestamp":1773096786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-market surveillance of antiretroviral drug quality in Tanzania in the context of rising HIV drug resistance"],"prefix":"10.1038","volume":"16","author":[{"given":"Eulambius M.","family":"Mlugu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob B.","family":"Mhagama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael Zozimus","family":"Sangeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Kunambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Samwel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nellin","family":"Shiletiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goodluck","family":"Gotora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunzy M.","family":"Chambiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damas","family":"Matiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danstan","family":"Hipolite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonah H.","family":"Mwalwisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam Mitangu","family":"Fimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"43655_CR1","unstructured":"WHO. HIV statistics, globally and by WHO region. (2025). https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/who-ias-hiv-statistics_2025-new.pdf. Accessed 5 Sept 2025."},{"key":"43655_CR2","unstructured":"WHO. HIV\/AIDS key facts. (2025). https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf. Accessed 5 Sept 2025."},{"key":"43655_CR3","unstructured":"UNAIDS. Country progress report-United Republic of Tanzania. (2020). https:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/TZA_2020_countryreport.pdf. Accessed 23 Aug 2025."},{"key":"43655_CR4","unstructured":"UN. UNAIDS Issues New Fast-Track Strategy to & End, A. I. D. S. by (2030). https:\/\/www.pedaids.org\/2014\/11\/20\/unaids-issues-new-fast-track-strategy-to-end-aids-by2030\/#:~:text=Only%20if%20these%20targets%20are,treatment%20with%20suppressed%20viral%20loads"},{"key":"43655_CR5","unstructured":"CDC, Tanzania & HIV Impact Survey: Tracking Progress and Informing Action. (2022). https:\/\/www.cdc.gov\/globalhealth\/stories\/2023\/tanzania-hiv-impact-surve.html. Accessed 28 Dec 2024."},{"key":"43655_CR6","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.puhip.2022.100240","volume":"3","author":"YH Wada","year":"2022","unstructured":"Wada, Y. H. et al. Falsified and substandard medicines trafficking: A wakeup call for the African continent. Public. Health Pract. (Oxf). 3, 100240 (2022).","journal-title":"Public. Health Pract. (Oxf)"},{"issue":"4","key":"43655_CR7","doi-asserted-by":"publisher","first-page":"e181662","DOI":"10.1001\/jamanetworkopen.2018.1662","volume":"1","author":"S Ozawa","year":"2018","unstructured":"Ozawa, S. et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: A systematic review and meta-analysis. JAMA Netw. Open. 1 (4), e181662 (2018).","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"43655_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jcpt.12226","volume":"40","author":"T Wang","year":"2015","unstructured":"Wang, T., Hoag, S. W., Eng, M. L., Polli, J. & Pandit, N. S. Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and Internet pharmacies. J. Clin. Pharm. Ther. 40 (1), 68\u201375 (2015).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"3","key":"43655_CR9","doi-asserted-by":"publisher","first-page":"e011423","DOI":"10.1136\/bmjgh-2022-011423","volume":"8","author":"NT Do","year":"2023","unstructured":"Do, N. T., Boupha, P., Newton, P. N. & Caillet, C. The quality of antiretroviral medicines: An uncertain problem. BMJ Glob. Health 8(3), e011423 (2023).","journal-title":"BMJ Glob. Health"},{"issue":"1","key":"43655_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4314\/tmj.v21i1.39202","volume":"21","author":"MH Chambuso","year":"2007","unstructured":"Chambuso, M. H., Ngassapa, O. D., Sayi, J. G., Jande, M. B. & Mohamed, Z. Quality of antiretroviral drugs, stavudine and indinavir capsules available in the Tanzanian market. Tanzan. Med. J. 21 (1), 8\u201312. https:\/\/doi.org\/10.4314\/tmj.v21i1.39202 (2007).","journal-title":"Tanzan. Med. J."},{"key":"43655_CR11","first-page":"1","volume":"4","author":"E Kamangu","year":"2017","unstructured":"Kamangu, E. et al. UV visible spectrophotometric determination of the quality of antiretroviral drugs distributed in Kinshasa. Open. Access Libr. J. 4, 1\u20138 (2017).","journal-title":"Open. Access Libr. J."},{"issue":"1","key":"43655_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12981-017-0147-x","volume":"14","author":"MP Djobet","year":"2017","unstructured":"Djobet, M. P. et al. Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in Cameroon. AIDS Res. Ther. 14 (1), 19 (2017).","journal-title":"AIDS Res. Ther."},{"key":"43655_CR13","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1093\/cid\/ciaa1161","volume":"73","author":"A Trevor","year":"2021","unstructured":"Trevor, A. et al. AFRICOS study group, pretreatment and acquired antiretroviral drug resistance among persons living with HIV in four African countries. Clin. Infect. Dis. 73, e2311\u2013e2322 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"43655_CR14","first-page":"e2311","volume":"73","author":"ME Mayer","year":"2020","unstructured":"Mayer, M. E. et al. Pre-treatment and acquired antiretroviral drug resistance among persons living with HIV in four African countries. Clin. Infect. Dis. 73, e2311\u2013e2322 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"43655_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40360-021-00514-w","volume":"22","author":"S Mziray","year":"2021","unstructured":"Mziray, S. et al. Quality of selected anti-retroviral medicines: Tanzania Mainland market as a case study. BMC Pharmacol. Toxicol. 22 (1), 46 (2021).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"43655_CR16","unstructured":"United Republic of Tanzania, Ministry of Health. Guidelines for developing and implementing medicines post marketing surveillance programme. (2019). https:\/\/www.tmda.go.tz\/uploads\/files\/PMS%20GUIDELINES%20FINAL%20OG.pdf"},{"issue":"6","key":"43655_CR17","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.24-0145","volume":"111","author":"EM Mlugu","year":"2024","unstructured":"Mlugu, E. M. et al. A comprehensive assessment of quality of antimalarial medicines in mainland Tanzania: insights from five years of postmarket surveillance. Am. J. Trop. Med. Hyg. 111 (6), 1215\u20131222 (2024).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"43655_CR18","unstructured":"MoH [Tanzania Mainland] National Guidelines for the Management Of HIV and AIDS-April. (2019). https:\/\/nacp.go.tz\/download\/national-guidelines-for-the-management-of-hiv-and-aids-april-2019\/. Accessed 6 Jan 2025."},{"key":"43655_CR19","unstructured":"GPHF. The GPHF-Minilab\u2122\u2014Protection against Counterfeit Medicines (2017). https:\/\/www.gphf.org\/en\/minilab\/index.htm"},{"key":"43655_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-016-0088-0","volume":"9","author":"R Ravinetto","year":"2016","unstructured":"Ravinetto, R. et al. Fighting poor-quality medicines in low- and middle-income countries: The importance of advocacy and pedagogy. J. Pharm. Policy Pract. 9, 36 (2016).","journal-title":"J. Pharm. Policy Pract."},{"key":"43655_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-023-00617-1","volume":"16","author":"P Ipagala","year":"2023","unstructured":"Ipagala, P. et al. Impact of COVID-19 on the supply chain of essential health commodities: A mixed method study, in Dar es Salaam, Tanzania. J. Pharm. Policy Pract. 16, 103 (2023).","journal-title":"J. Pharm. Policy Pract."},{"key":"43655_CR22","unstructured":"Tanzania, F., Drugs & Authority Guidelines on Format and Content of Labels for Medicinal Products. (2015). https:\/\/www.tmda.go.tz\/uploads\/documents\/en1544792979-guidelines%20on%20format%20and%20content%20of%20labels%20for%20medicinal%20products.pdf. Accessed 10 Dec 2024."},{"key":"43655_CR23","doi-asserted-by":"publisher","DOI":"10.4172\/2167-7689.1000191","volume":"6","author":"S Mziray","year":"2017","unstructured":"Mziray, S. et al. Post marketing surveillance of anti-malarial medicines in Tanzania. Pharm. Regul. Aff. 6, 191 (2017).","journal-title":"Pharm. Regul. Aff."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43655-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:26:06Z","timestamp":1776666366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43655-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43655"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43655-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not involve human participants. Therefore, ethical clearance was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"12815"}}